Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RVU.WAthis companyRyvu Therapeutics S.A.	PLN 16.32	-6.19×	11.64×	10.06×	-5.67×	-1415.4%	-188.0%	-196.2%	-162.6%	-188.0%	-74.8%	-18.8%	1.33×	-0.11×	-13.88×	2.26×	0.0%	2	-1.05	1	D+
BCX.WABioceltix S.a.	PLN 68.70	-25.61×	5.29×	0×	-19.22×	-79.7%	0.0%	0.0%	0.0%	-20.7%	-23.5%	-3.6%	0×	4.09×	-82.9×	32.51×	0.0%	2	70.81	2	C
BIO.WABioton S.a.	PLN 3.49	97.72×	0.56×	1.17×	7.42×	-205.5%	34.2%	4.5%	1.2%	0.6%	0.8%	0.7%	0.1×	0.95×	2.19×	1.41×	0.0%	4	-0.67	3	B
CTX.WACaptor Therapeutics Spolka Akcyjna	PLN 53.60	-9.46×	16.92×	85.26×	-7.99×	-150.3%	-14.0%	-1141.8%	-901.2%	-178.9%	-195.8%	-9.2%	0.15×	0.15×	-188.01×	2.27×	0.0%	2	7.35	1	C-
ENE.WACentrum Medyczne ENEL-MED S.A.	PLN 20.00	37.39×	2.62×	0.57×	7.78×	354.0%	9.3%	2.4%	1.5%	6.9%	3.0%	4.5%	1.84×	3.02×	2×	0.6×	0.0%	6	2.29	3	B
MAB.WAMabion S.A.	PLN 7.72	-1.8×	2.31×	7.16×	-2.73×	-128.9%	-110.5%	-334.8%	-397.4%	-128.2%	-77.5%	-37.7%	0.26×	-0.14×	-65.62×	0.29×	0.0%	4	-3.73	1	D+
Peer median	—	-1.8×	2.62×	1.17×	-2.73×	-128.9%	0.0%	0.0%	0.0%	-20.7%	-23.5%	-3.6%	0.15×	0.95×	-65.62×	1.41×	0.0%	4	2.29	2	—